Denovo Biopharma Creates Gene Registry Program To Support A Precision Medicine For Treatment-Resistant Depression

Denovo Biopharma launched a gene registry to identify biomarkers correlated with responses to antidepressants to investigate drug efficacy for treatment-resistant depression (TRD). The company is inviting people with TRD to visit the portal to identify whether they or someone they know with TRD may be eligible to participate in a biomarker-guided global Phase 2b clinical trial called the “ENLIGHTEN” study. People with TRD have been diagnosed with major depressive disorder (MDD) and have not had an adequate response after treatment with two different antidepressant trials, each taken for an adequate dose and duration.

Denovo Biopharma is using the . . .